Heikkila R E, Manzino L
Eur J Pharmacol. 1984 Aug 17;103(3-4):241-8. doi: 10.1016/0014-2999(84)90483-7.
Two aryl 1,4-dialkylpiperazines (GBR 12909 and GBR 13098) and one aryl 1,4-dialkenylpiperazine (GBR 13069) were very potent inhibitors of [3H]dopamine uptake in vitro in tissue slices obtained from rat neostriatum (IC50 values between 40 and 51 nM). Each compound was considerably weaker as an inhibitor of [3H]norepinephrine uptake in tissue slices obtained from rat occipital cortex (IC50 values between 560 and 2600 nM). These compounds thus are relatively specific inhibitors of [3H]dopamine uptake in vitro. The three compounds caused ipsilateral circling in rats with unilateral lesions of the nigrostriatal pathway as well as increased locomotor activity in naive mice, both of which could be greatly attenuated by pretreatment of the rodents with the dopamine receptor antagonist haloperidol. It thus follows that the compounds have dopaminergic activity in vivo. Ex vivo experiments with GBR 13069 (drug administration in vivo, uptake in vitro) suggested that these compounds may have the same relative specificity as dopamine uptake blockers in vivo. These compounds should prove to be useful pharmacological agents.
两种芳基1,4 - 二烷基哌嗪(GBR 12909和GBR 13098)以及一种芳基1,4 - 二烯基哌嗪(GBR 13069)在体外对从大鼠新纹状体获取的组织切片中的[³H]多巴胺摄取具有很强的抑制作用(IC50值在40至51 nM之间)。在从大鼠枕叶皮质获取的组织切片中,每种化合物作为[³H]去甲肾上腺素摄取抑制剂的活性则弱得多(IC50值在560至2600 nM之间)。因此,这些化合物在体外是相对特异性的[³H]多巴胺摄取抑制剂。这三种化合物在黑质纹状体通路单侧损伤的大鼠中引起同侧转圈,并且在未处理的小鼠中增加运动活性,而这两种效应均可通过用多巴胺受体拮抗剂氟哌啶醇预处理啮齿动物而大大减弱。由此可见,这些化合物在体内具有多巴胺能活性。使用GBR 13069进行的体外实验(体内给药,体外摄取)表明,这些化合物在体内可能具有与多巴胺摄取阻滞剂相同的相对特异性。这些化合物应被证明是有用的药理试剂。